Anzeige
Mehr »
Mittwoch, 03.09.2025 - Börsentäglich über 12.000 News
Geheime Uran-Aktie: Ist das der historische "New Deal"-Moment für amerikanischen Uransektor?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P200 | ISIN: KYG0146B1032 | Ticker-Symbol: 4RY
Tradegate
02.09.25 | 21:21
17,200 Euro
-1,15 % -0,200
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
AKESO INC Chart 1 Jahr
5-Tage-Chart
AKESO INC 5-Tage-Chart
RealtimeGeldBriefZeit
16,70017,10019:13
16,70017,10018:23

Aktuelle News zur AKESO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
AKESO Aktie jetzt für 0€ handeln
DiAkeso, Inc.: Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy144HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized...
► Artikel lesen
MoHSBC initiates Akeso stock with Buy rating on strong 1H25 results8
DoAKESO Once Plummets 7.5% on ~5% Discounted Shr Placement & Shareholder Sell-Down2
DoAKESO (09926): PLACING OF NEW SHARES UNDER GENERAL MANDATE AND PLACING OF EXISTING SHARES1
27.08.Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst7
27.08.Akeso shares surge as cancer drug achieves key milestone in China trial7
27.08.AKESO Opens 4.7% Higher; 1H Rev. Soars ~38%, Loss Widens5
26.08.Positive Studiendaten von Akeso beflügeln Aktie von Summit Therapeutics11
26.08.Summit Therapeutics stock rises after Akeso reports positive trial data2
26.08.Akeso, Summit's PD-1xVEGF drug meets overall survival goal for the first time in a lung cancer trial1
26.08.Akeso, Inc.: Akeso's 2025 Interim Results: Commercial Sales Reach New All-Time Highs260IO 2.0 + ADC 2.0 Strategy Builds a "Next-Generation" Platform with Global Competitive Edge Key Highlights: Final analysis of HARMONi-A Study: Ivonescimab met the...
► Artikel lesen
26.08.AKESO (09926): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE1
26.08.AKESO (09926): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 20251
25.08.Akeso scores twice in pair of phase 3 trials, teeing up regulatory submission in China1
25.08.Akeso: Gumokimab, Manfidokimab Achieve Primary Endpoints In Phase 3 Trials2
25.08.Akeso's antibody treatments show positive results in phase 3 trials2
25.08.Positive Phase-3-Studiendaten beflügeln Akeso-Aktie12
25.08.Akeso, Inc.: Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Ra) for Atopic Dermatitis Achieve Primary Endpoints84HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) ("Akeso" or "the Company") today announced positive results from its Phase 3 clinical trial of...
► Artikel lesen
22.08.HSI Closes Midday at 25,184, Up 80 pts; HSTI Closes Midday at 5,586, Up 88 pts; XPENG Up over 10%; TENCENT, SINO BIOPHARM, CHOW TAI FOOK, HUA HONG SEMI, AKESO Hit New Highs14
20.08.Akeso, Inc.: First Patient Dosed in Pivotal Phase III Trial of Cadonilimab (PD-1/CTLA-4) for Perioperative Treatment of Resectable Gastric Cancer95HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal...
► Artikel lesen
Weiter >>
83 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3